Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers January 12, 2015, Seattle WA, TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase…

Details

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each “unit” consisting of…

Details

TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a…

Details

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease

Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox. SEATTLE, WASHINGTON, October 22, 2014 — TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and…

Details

Tapimmune, a Biotech Company Focused on Stimulating the Body’s Own Immune System to Fight Cancer

TapImmune, a biotech company focused on stimulating the body’s own immune system to fight cancer. Please listen to the interview with host Eric Michaels of eHealth Radio Network and TapImmune CEO Glynn Wilson here: http://ehealthradio.podbean.com/e/tapimmune-a-biotech-company-focused-stimulating-the-body%E2%80%99s-own-immune-system-to-fight-cancer/ Glynn Wilson, Chairman and CEO of Tapimmune, a biotech company focused on Immunotherapy, which stimulate the body’s own immune system…

Details

TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs

I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company now has multiple clinical trials underway at the Mayo Clinic in…

Details

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer

All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set…

Details